Telix Pharmaceuticals Limited

Telix Pharmaceuticals Limited reported revenue of $803.8 million for fiscal year 2025, generating gross profit of $426.4 million. The company achieved operating profit of $29.8 million but recorded a net loss of $7.1 million for the year, primarily due to finance costs of $40.9 million. Total comprehensive loss was $14.1 million. The balance sheet shows total assets of $1.16 billion with net assets of $415.4 million, while total liabilities stood at $748.6 million including borrowings of $405.0 million. Cash flow from operations was negative $17.3 million, with significant cash used in investing activities of $285.9 million primarily for acquisitions and capital expenditures. The company ended the year with cash and cash equivalents of $141.9 million.

Key Takeaways